Eton Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Financial statement amounts are in thousands of dollars, except per-share data and share counts. The interim financial statements are unaudited.
Business context
Eton is a specialty pharmaceutical company focused on hospital injectable and pediatric rare-disease products. Its commercial portfolio includes Biorphen and Alkindi Sprinkle; it also receives royalties from EM-100, marketed by Bausch Health. In February 2021, Eton sold three pediatric neurology product candidates to Azurity and may receive further milestone revenue, including upon FDA review and commercial launch.
Financial performance and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Net revenue | $3.067 million | $20,000 | $14.964 million | $119,000 |
| Gross profit (loss) | $2.931 million | $(8,000) | $13.238 million | $(11,000) |
| Operating expenses | $5.256 million | $4.530 million | $10.200 million | $13.408 million |
| Operating income (loss) | $(2.325) million | $(4.538) million | $3.038 million | $(13.419) million |
| Net income (loss) | $(2.016) million | $(4.730) million | $3.100 million | $(13.779) million |
| Basic and diluted earnings (loss) per share | $(0.08) | $(0.23) | $0.12 | $(0.70) |
Q2 gross margin was approximately 95.6%; six-month gross margin was approximately 88.5%. These figures were substantially affected by licensing milestone revenue and are not solely a measure of product economics. Q2 revenue included $2.5 million in licensing milestones and $567,000 in product sales and royalties. Six-month revenue included $14.0 million in licensing milestones and $964,000 in product sales and royalties.
At June 30, cash and cash equivalents were $25.802 million, versus $21.295 million at year-end 2020. Current assets were $29.075 million and current liabilities $3.106 million. Total liabilities were $9.170 million; stockholders’ equity was $20.736 million. The company reported $7.0 million of gross SWK loan principal, with $749,000 current and $5.856 million long-term net of discount. The $361,000 PPP loan and accrued interest were forgiven in May, producing a $365,000 gain. Eton repaid its $150,000 EIDL loan, plus accrued interest, in July 2021.
For the six months, the filing’s MD&A describes operating cash flow as provided of $3.346 million; investing cash flow provided $697,000, including $700,000 from the lab-equipment sale; financing cash flow provided $464,000. Cash increased $4.507 million. The cash-flow statement’s operating-activity line is labeled “net cash used” despite showing a positive $3.346 million, an internal presentation inconsistency.
Changes versus comparable periods
- Revenue rose sharply from minimal prior-year sales, primarily because of licensing milestones associated with the Azurity transaction and other product milestones. Product sales and royalties also increased.
- Six-month operating results moved to income from a substantial loss, reflecting increased revenue and lower R&D spending. The comparison benefited from $4.764 million in Alkindi Sprinkle licensing costs recorded in the first half of 2020.
- Q2 net loss narrowed year over year, while R&D and G&A expense increased. Higher Alkindi Sprinkle marketing and distribution costs contributed to G&A growth.
- Cash rose from year-end, and operating cash flow improved compared with the $10.070 million used in the first half of 2020. The 2020 period also included $7.756 million of equity-offering proceeds; there were no such proceeds in the first half of 2021.
Outlook, risks and unusual items
- Management expects further growth in 2021 and beyond from greater penetration of approved products, licensing revenue and potential additional products subject to FDA approval. No specific revenue or earnings guidance was provided.
- Management believed June 30 cash would fund operating expenses and capital needs for at least twelve months from the filing date, based on sales and spending assumptions. It cautioned that cash could be used sooner and future financing might be needed; financing may be unavailable or dilutive. Delays in sales growth, development or regulatory approval could require operations to be scaled back or discontinued.
- Revenue depends in part on milestone events and regulatory decisions, while product revenue is subject to distributor discounts, chargebacks, fees and, for Biorphen, returns. Estimates that differ from actual amounts could affect revenue and earnings.
- Eton closed its Lake Zurich laboratory operation in March and sold the equipment in May for $700,000, recording a $181,000 gain. It also recorded the $365,000 PPP-loan forgiveness gain. These are unusual items that increased reported first-half income.
- Eton paid Crossject $500,000 under a June agreement for U.S. and Canadian rights to a hydrocortisone autoinjector under development; further milestone payments, approval payments and royalties may be due. The filing identifies no material pending or threatened litigation and reports no material changes to the previously disclosed risk factors.
Important facts for investors to verify
- Reconcile the cash-flow statement’s “net cash used” label with its positive $3.346 million amount and management’s description of cash provided.
- Confirm the composition, timing and recognition of the $14.0 million in first-half licensing milestones, and the conditions for additional Azurity and Bausch Health payments.
- Track commercial uptake and economics of Biorphen and Alkindi Sprinkle, including promotional costs, product returns, chargebacks and royalties.
- Review SWK debt service, covenants and any negotiated EBITDA or revenue covenant targets, as well as the July 2021 EIDL repayment.
- Assess the cash-runway estimate against actual sales, development spending and FDA timelines; evaluate the possible dilution or availability of future financing.